Cellectis (CLLS) Net Income (2015 - 2026)
Cellectis (CLLS) posted quarterly Net Income of -$17.8 million for Q1 2026, up 2.0% year-over-year from -$17.4 million in Q1 2025, and up 83.17% quarter-over-quarter from -$105.5 million in Q4 2025.
Cellectis (CLLS) Net Income (2015 - 2026) Analysis & Trends
Cellectis' Net Income history runs 12 years deep, the most recent figure standing at -$17.8 million for Q1 2026.
- In Q1 2026, Net Income rose 2.0% year-over-year to -$17.8 million; the TTM figure through Mar 2026 stood at -$85.2 million (down 65.09% YoY), while the FY2023 annual figure was $8.4 million, up 154.69% from the prior year.
- Net Income for Q1 2026 stood at -$17.8 million, up from -$105.5 million in the prior quarter.
- The five-year high for Net Income was $59.8 million in Q2 2022, with the low at -$105.5 million in Q4 2025.
- The 5-year median for Net Income is -$4.7 million (2023), against an average of -$6.4 million.
- The sharpest annual moves came in 2022 and 2025: Net Income surged 265.42% in 2022, then slumped 156.49% in 2025.
- Cellectis' Net Income stood at -$2.9 million in 2022, then jumped by 557.93% to $13.1 million in 2023, then sank by 414.52% to -$41.1 million in 2024, then tumbled by 156.49% to -$105.5 million in 2025, then soared by 83.17% to -$17.8 million in 2026.
- Business Quant data shows CLLS's Net Income at -$17.8 million in Q1 2026, -$105.5 million in Q4 2025, and $22.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | -17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.77 Mn |
| Dec 31, 2025 | -105.54 Mn |
| Sep 30, 2025 | 22.41 Mn |
| Jun 30, 2025 | 15.65 Mn |
| Mar 31, 2025 | -18.13 Mn |
| Dec 31, 2024 | -41.15 Mn |
| Sep 30, 2024 | 7.64 Mn |
| Jun 30, 2023 | 13.08 Mn |
| Mar 31, 2023 | -4.69 Mn |
| Dec 31, 2022 | -2.86 Mn |
| Sep 30, 2022 | -5.72 Mn |
| Jun 30, 2022 | 59.83 Mn |
| Mar 31, 2022 | -5.62 Mn |
| Dec 31, 2021 | -6.65 Mn |
| Sep 30, 2021 | -44.56 Mn |
| Jun 30, 2021 | -36.17 Mn |
| Mar 31, 2021 | -10.03 Mn |
| Dec 31, 2020 | 26.75 Mn |
| Sep 30, 2020 | -30.25 Mn |
| Jun 30, 2020 | -35.09 Mn |